ALPEGA-GROUP
17.4.2024 14:01:57 CEST | Business Wire | Press release
Alpega, a global leader in logistics SaaS software, announces its recognition as a Challenger in the 2024 Gartner Magic Quadrant for Transportation Management Systems (TMS). We believe this acknowledgment underscores Alpega’s unwavering commitment to delivering cutting-edge solutions tailored to meet the evolving demands of the transportation industry. The Gartner report evaluates vendors based on their completeness of vision and ability to execute.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417652913/en/
(Photo: Alpega)
Alpega serves global customers with deployments in all geographies, addressing diverse sectors such as automotive, retail, fast-moving consumer goods, and manufacturing, Alpega places significant emphasis on fostering collaboration with carriers, optimizing transportation procurement, and championing environmental, social, and governance (ESG) initiatives.
Backed by a history of exceptional customer retention rates and proactive engagement, Alpega pledges unparalleled support and satisfaction. As the company continues to expand its business, it remains steadfast in its commitment to deliver creative solutions to the problems remaining in the transportation space, solidifying its status as a trusted partner in the ever-evolving domain of logistics. We invite you to learn more about our recognition by accessing the complete Gartner Magic Quadrant report [here].
Alpega CEO, Todd DeLaughter, remarked, “As we celebrate our recognition as a Challenger in the 2024 Gartner Magic Quadrant, we reaffirm our commitment to pushing the boundaries of innovation and excellence in transportation management technology. With a customer-centric ethos and an unyielding drive for progress, we are poised to lead the industry towards a future defined by efficiency, sustainability, unparalleled service and most importantly, unlocking business value for our customers.”
Gartner subscribers can access the complete Magic Quadrant for Transportation Management Systems here Gartner Disclaimer.
Recognized as Alpega Group from 2020 to 2024 and as inet-logistics from 2011 to 2019.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Alpega
Alpega is a leading global logistics SaaS software company committed to providing comprehensive end-to-end solutions that cater to all transport requirements. Our overarching mission is to enable shippers and carriers to navigate today's logistics challenges efficiently through digitalization, thereby driving smarter logistics for a greener tomorrow
Harnessing the extensive assets of our carrier network, Alpega delivers tangible benefits across Execution, Planning, Sourcing, and Payment solutions. As the premier SaaS provider offering Transport Management Systems (TMS) for shippers, alongside an 80,000-strong open carrier network covering approximately 10% of all commercial trucks in Europe, we stand at the forefront of innovation and efficiency. For carriers, our connectivity spans three premier freight exchanges in Europe, with notable leadership in Iberia, Romania, Central, and South-eastern European regions, facilitating seamless matching of freight loads with transportation capacity.
With over three decades of transportation expertise, we empower businesses to streamline their supply chain planning and execution, resulting in reduced costs and enhanced visibility. Alpega's suite of solutions synergistically creates added value for our customers. Our community comprises 80,000 carriers and 200,000 members, electronically interconnected each day to efficiently manage vital transport operations. Operating in 80 countries worldwide, Alpega boasts a diverse team of over 500 professionals representing 31 nationalities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417652913/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
